DEF: SBC Medical Group Holdings to Hold Virtual Annual Meeting, Proposes Board Declassification and Ratifies Auditor

SBC Medical Group Holdings Incorporated announced its 2025 annual meeting of stockholders, to be held virtually on June 13, 2025, where key proposals include the election of directors, ratification of its independent auditor, and a significant amendment to declassify its board of directors.

Summary

• SBC Medical Group Holdings Incorporated will host its 2025 annual meeting of stockholders virtually on Friday, June 13, 2025, at 10:00 a.m. Japan Standard Time (Thursday, June 12, 2025, 6:00 p.m. Pacific Time).
• Key proposals for stockholder vote include the election of two directors (Ken Edahiro and Mike Sayama), the ratification of MaloneBailey, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and a significant amendment to declassify the board of directors.
• If the declassification proposal is approved, all current directors' terms will convert to one-year terms, ending at the 2026 annual meeting, with subsequent annual elections for all director nominees.
• The company's common stock began trading on the Nasdaq Global Market under the symbol SBC on September 18, 2024, following the business combination with Pono Capital Two, Inc.
• As of April 15, 2025, there were 103,611,251 shares of common stock outstanding.
• Revenues from related parties increased to $195,173,889 for the twelve months ended December 31, 2024, up from $182,738,049 in 2023.
• CEO Yoshiyuki Aikawa's salary for 2024 was $14,506,032, while CFO and COO Yuya Yoshida received $304,404, and Principal Accounting Officer Ryoji Murata received $136,990.

Sentiment

Score: 6

Explanation: The document is a standard proxy statement, primarily informative and neutral. The proposed board declassification is a positive governance move, and the company shows growth in related party revenues. However, the 'controlled company' status and extensive related party transactions, along with the CEO's high compensation, introduce some areas of potential concern or scrutiny, preventing a higher score.

Positives

• The proposal to declassify the board of directors is a positive corporate governance initiative, aiming to enhance accountability and responsiveness to stockholders by moving to annual director elections.
• The company maintains a majority of independent directors on its board and key committees (Audit, Compensation, Nominating & Corporate Governance), aligning with Nasdaq requirements.
• Hosting a virtual annual meeting is expected to enable greater stockholder attendance and participation globally, improve meeting efficiency, and reduce costs and environmental impact.
• Revenues from related parties showed growth, increasing from $182,738,049 in 2023 to $195,173,889 in 2024.
• The company disposed of non-core subsidiaries (Kijimadairakanko Inc. and Skynet Academy Co., Ltd.) to entities owned by the CEO, aiming to concentrate business and management resources on its main medical operations.
• The amended SBC Operating Agreement (SBCOA) with Medical Corporations (MCs), effective April 1, 2025, introduces a revised fee structure with reduced first-year fees for newly opened clinics, intended to facilitate new clinic establishment and support long-term business expansion.

Negatives

• The company's status as a 'controlled company' due to Dr. Yoshiyuki Aikawa's approximately 89.45% voting power means it could potentially rely on exemptions from certain Nasdaq corporate governance requirements, which might reduce protections for minority stockholders, even though it currently does not intend to.
• A substantial portion of the company's financial transactions, including revenues, receivables, and payables, are with related parties, which, despite oversight, can raise concerns about potential conflicts of interest.
• The CEO's salary of $14,506,032 in 2024 is significantly higher than other executive compensations disclosed, which might be a point of scrutiny for some investors.

Risks

• **Controlled Company Status**: Dr. Yoshiyuki Aikawa's control of approximately 89.45% of the voting power allows the company to qualify as a 'controlled company' under Nasdaq rules, potentially enabling it to bypass certain corporate governance requirements (e.g., majority independent board, fully independent nominating and compensation committees). While the company currently does not intend to use these exemptions, it retains the option to do so, which could impact minority stockholder protections.
• **Related Party Transactions**: The company engages in numerous material transactions with entities controlled by or related to its CEO and other management. While the Audit Committee oversees these, such extensive related party dealings inherently carry potential for conflicts of interest.
• **Enforceability of Executive Covenants**: The enforceability of non-compete and non-solicitation provisions in executive employment agreements is uncertain due to the application of various state laws, which could impact the company's ability to protect its business interests post-employment.
• **Internal Control Over Financial Reporting**: The company's legal predecessor, Pono, had a previously disclosed material weakness in its internal control over financial reporting, which led to financial statement restatements. While this relates to the predecessor, it highlights past challenges in financial oversight.

Future Outlook

The company is pursuing a long-term growth strategy focused on expanding and stabilizing its business foundation by creating an environment that facilitates the establishment of new clinics by Medical Corporations (MCs). This includes amending the SBC Operating Agreement (SBCOA) with MCs, effective April 1, 2025, to reduce initial cost burdens for newly established clinics and implement service utilization-based fees from the second year onward.

Management Comments

• "We believe hosting a virtual annual meeting enables greater stockholder attendance and participation from any location around the world, improves meeting efficiency and our ability to communicate effectively with our stockholders, and reduces the cost and environmental impact of our annual meeting." (Taiki Sakaguchi, Corporate Secretary)
• The company's executive compensation program is designed to attract, motivate, incentivize, and retain executives who contribute to long-term success, provide fair and competitive compensation, ensure high retention value, reward high performance, and align executive interests with stockholders through long-term equity incentives.

Industry Context

SBC Medical Group Holdings operates within the Japanese medical services sector, specifically providing management and consulting services to Medical Corporations (MCs) that own and operate treatment centers. This business model is structured to comply with the Japanese Medical Care Act. The company's strategic focus on facilitating new clinic establishment and expanding its business foundation aligns with growth trends in the broader aesthetic and healthcare industries, particularly in the Japanese market.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• The audit committee's responsibilities include reviewing and discussing with management and auditors the company's major litigation and risk exposures. No specific new legal proceedings are detailed in this document.

Related Party Transactions

• **Convertible Promissory Note**: Pono (the legal predecessor) entered into a Convertible Promissory Note with the Company on May 18, 2023, for $1,000,000, which was amended on February 27, 2024, to increase the principal to $2,700,000. This note automatically converted into Class A Common Stock at the closing of the Business Combination.
• **Non-Redemption Agreement**: In connection with the extension of the business combination deadline, the Company and its Sponsor entered into non-redemption agreements with certain unaffiliated stockholders who agreed not to redeem 998,682 shares of Class A common stock. As incentive, 860,435 shares of common stock were issued to Mehana Capital LLC (the Sponsor) in February 2025.
• **Medical Service Corporations (MCs)**: SBC Medical Sub has franchisor-franchisee contracts and service contracts with six MCs (Medical Corporation Shobikai, Kowakai, Nasukai, Aikeikai, Jukeikai, Ritz Cosmetic Surgery) and service contracts with two additional MCs (Medical Corporation Association Furinkai, Junikai). All MCs are deemed related parties due to relatives of the CEO being members.
• **Revenues from Related Parties**: Totaled $195,173,889 in 2024 (vs. $182,738,049 in 2023), with Medical Corporation Shobikai ($53,862,520), Medical Corporation Kowakai ($46,756,189), and Medical Corporation Nasukai ($46,355,437) being the largest contributors in 2024.
• **Accounts Receivable from Related Parties**: Totaled $28,846,680 as of December 31, 2024 (vs. $33,676,672 in 2023).
• **Finance Lease Receivables from Related Parties**: Totaled $14,390,167 as of December 31, 2024 (vs. $9,564,053 in 2023).
• **Long-term Investments in MCs**: Totaled $17,820,910 as of December 31, 2024 (vs. $19,811,555 in 2023).
• **Accounts Payable to Related Parties**: Totaled $659,044 as of December 31, 2024 (vs. $0 in 2023), primarily to Japan Medical & Beauty Inc.
• **Advances from Customers (Related Parties)**: Totaled $11,739,533 as of December 31, 2024 (vs. $23,058,175 in 2023).
• **Notes Payable to Related Parties**: Totaled $31,589 as of December 31, 2024 (vs. $15,317,422 in 2023).
• **Due to Related Party (Yoshiyuki Aikawa)**: $2,823,590 as of December 31, 2024 (vs. $3,583,523 in 2023). These loans are non-secured, interest-free, and due on demand.
• **Allowance for Credit Loss Movement**: Ending balance of $2,836,013 in 2024 (vs. $3,238,209 in 2023), with a provision for credit loss of $622,804 and a reversal of $1,025,000 in 2024.
• **Other Income from Related Parties**: Totaled $2,673,077 in 2024 (vs. $0 in 2023).
• **Purchases from Japan Medical & Beauty Inc.**: $8,472,202 in 2024 (vs. $2,842,588 in 2023) for medical equipment and cosmetics, recognized in cost of revenues.
• **Disposal of Subsidiaries**: Kijimadairakanko Inc. and Skynet Academy Co., Ltd. were sold to entities owned by CEO Yoshiyuki Aikawa on December 23, 2024, for cash considerations of $0 and $446,460 respectively, to concentrate on the main medical business.
• **Amended SBC Operating Agreement (SBCOA)**: Effective April 1, 2025, with revised fee structure for MCs, including reduced first-year fees for new clinics and service utilization-based fees from the second year, aiming to facilitate new clinic establishment.

Stakeholder Impact

• **Shareholders**: Will have the opportunity to vote on significant corporate governance changes, including board declassification, which could enhance board accountability. The virtual meeting format aims to increase participation. However, the CEO's substantial voting control as a 'controlled company' may limit the influence of other shareholders.
• **Employees/Management**: New executive appointments (CFO, CSO) are noted, and the equity incentive plan is designed to align management's interests with stockholders. Executive compensation details are provided.
• **Customers (via MCs)**: The revised fee structure for Medical Corporations (MCs) is intended to facilitate the establishment of new clinics, potentially leading to expanded access to medical services and improved customer satisfaction.
• **Creditors/Suppliers**: The detailed related party financial balances (receivables, payables, notes) indicate ongoing financial relationships that impact the company's financial health and operational stability.

Next Steps

• Hold the 2025 annual meeting of stockholders virtually on June 13, 2025, for stockholder votes on director elections, auditor ratification, and board declassification.
• If Proposal 3 (board declassification) is approved, all directors will serve until the 2026 annual meeting, and all director nominees will stand for annual election thereafter.
• The company will publish preliminary or final voting results in a Current Report on Form 8-K within four business days following the annual meeting.
• The audit committee will reconsider the appointment of MaloneBailey, LLP if stockholders do not ratify their appointment.
• The amended and renewed SBC Operating Agreement (SBCOA) with Medical Corporations (MCs) will continue, with terms automatically renewed for one year unless terminated.

Key Dates

Recommendation

Keywords

SBC Medical Group Holdings, Proxy Statement, Corporate Governance, Board Declassification, Annual Meeting, Nasdaq, Related Party Transactions, Executive Compensation, MaloneBailey LLP, Medical Services, Healthcare, Japan, SEC Filing